Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Single-Site, Open-Label Study of Efgartigimod in Patients With IgG4-Related Disease

NCT07025330 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT07025330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07025330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Single-Site, Open-Label Study of Efgartigimod in Patients With IgG4-Related Disease
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 12, 2025
Completion date
June 1, 2028
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

igg4-related disease